First person vaccinated during trial of new Ebola jab
Sign up now: Get ST's newsletters delivered to your inbox
Red Cross workers in personal protective equipment disinfect the house of a man who died of Ebola, in Mongbwalu, Democratic Republic of the Congo, on May 24.
PHOTO: REUTERS
- Oxford University began human trials on July 24 for a new vaccine targeting the Bundibugyo strain of Ebola causing a deadly outbreak in the DRC and Uganda.
- The vaccine trial uses technology similar to AstraZeneca's Covid-19 vaccine and aims to test safety and effectiveness in 50 healthy adults.
- The outbreak has killed over 1,000 people, spread rapidly, and has no approved vaccines yet, prompting urgent development and stockpiling of new treatments and vaccines.
AI generated
PARIS - A volunteer was injected on July 24 with the first dose of a rapidly developed vaccine targeting the Bundibugyo strain of Ebola driving a deadly outbreak in the Democratic Republic of Congo, Oxford University said.
More than 1,000 people have been killed in the DRC and Uganda since the outbreak emerged in May, according to the World Health Organization.
Researchers and health organisations have since been racing to get a vaccine or treatment for the relatively rare strain to the clinical trial stage where it is tested on humans.
Earlier in July, a team at Oxford University in the UK announced it was launching the first trial for its ChAdOx1 BDBV vaccine, which uses the same technology as AstraZeneca’s Covid-19 vaccine.
The first dose was administered to a 37-year-old volunteer named Ed Hunt in Oxford on July 24, a university spokesman told AFP.
“We’ve taken this vaccine candidate from concept to clinic in just eight weeks,” David Pulido-Gomez of Oxford’s Pandemic Sciences Institute said in a statement.
“Reaching this milestone in such a short timeframe reflects an extraordinary collaborative effort,” he added.
The trial received funding from the Coalition for Epidemic Preparedness Innovations, while the Serum Institute of India has already manufactured a stockpile of 620,000 doses.
The phase 1 trial plans to assess the safety and effectiveness of the vaccine in 50 health adults in the coming weeks. The researchers are currently recruiting more volunteers.
Given regulatory approval, the team is preparing for more clinical studies of the vaccine with partners in Uganda, Oxford said.
Several other Bundibugyo vaccine candidates are also being urgently developed towards the trial stage, while two potential treatments are being worked on.
The Ebola outbreak is the 17th in the DRC’s history, but just the third caused by the Bundibugyo strain, for which there are no approved vaccines or treatments.
WHO chief Tedros Adhanom Ghebreyesus warned last week that the outbreak had over the past month of July “expanded faster than any previous outbreak” of Ebola.
The outbreak has remained concentrated in the vast country’s mineral-rich and conflict-plagued northeastern province.
Cases of Ebola, which spreads through close contact and infected bodily fluids, have also been found in four other DRC provinces. AFP
